Diabetes, Obesity and Metabolism: Vol 23, No 3

Actions

Tools

Follow journal

Issue
Volume 23, Issue 3
Pages: 653-874
March 2021

Free Access

Cover Image, Volume 23, Issue 3

Jun Ito MD, Munenobu Nogami PhD, Yasuko Morita MD, Kazuhiko Sakaguchi MD, Hisako Komada MD, Yushi Hirota MD, Kenji Sugawara MD, Yoshikazu Tamori MD, Feibi Zeng MD, Takamichi Murakami MD, Wataru Ogawa MD,

First Published: 15 February 2021

The cover image is based on the Original Article Dose-dependent accumulation of glucose in the intestinal wall and lumen induced by metformin as revealed by 18F-labelled fluorodeoxyglucose positron emission tomography-MRI by Jun Ito et al., https://doi.org/10.1111/dom.14262.

Journal list menu

Tools

Follow journal

Diabetes, Obesity and Metabolism

Export Citations

Format

Type of import

COVER IMAGE

Cover Image, Volume 23, Issue 3

ISSUE INFORMATION

Diabetes, Obesity and Metabolism

COMMENTARIES

Hybrid closed-loop therapy: Where are we in 2021?

Genetically determined lean mass and dietary response

REVIEW ARTICLE

Mechanism of action of Imeglimin: A novel therapeutic agent for type 2 diabetes

ORIGINAL ARTICLES

A single-dose euglycaemic clamp study in two cohorts to compare the exposure of SAR341402 (insulin aspart) Mix 70/30 with US- and European-approved versions of insulin aspart Mix 70/30 and SAR341402 rapid-acting solution in subjects with type 1 diabetes

Effectiveness and safety of sodium-glucose co-transporter-2 inhibitors compared with dipeptidyl peptidase-4 inhibitors in older adults with type 2 diabetes: A nationwide population-based study

Dose-dependent accumulation of glucose in the intestinal wall and lumen induced by metformin as revealed by 18F-labelled fluorodeoxyglucose positron emission tomography-MRI

Inhibition of fatty acid synthase with FT-4101 safely reduces hepatic de novo lipogenesis and steatosis in obese subjects with non-alcoholic fatty liver disease: Results from two early-phase randomized trials

Weight loss-induced increase in fasting ghrelin concentration is a predictor of weight regain: Evidence from the Diabetes Remission Clinical Trial (DiRECT)

Treatment persistence in patients with type 2 diabetes treated with glucagon-like peptide-1 receptor agonists in clinical practice in Sweden

Association of weight loss and weight loss maintenance following diabetes diagnosis by screening and incidence of cardiovascular disease and all-cause mortality: An observational analysis of the ADDITION-Europe trial

Long-term outcomes of metabolic surgery in overweight and obese patients with type 2 diabetes in Asia

The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity

The effects of dipeptidyl peptidase-4 inhibitors on kidney outcomes

Flash glucose monitoring data analysed by detrended fluctuation function on beta-cell function and diabetes classification

Prediction of heart failure outcomes in patients with type 2 diabetes mellitus: Validation of the Thrombolysis in Myocardial Infarction Risk Score for Heart Failure in Diabetes (TRS-HFDM) in patients in the ACCORD trial

Cost-effectiveness analysis of empagliflozin versus sitagliptin as second-line therapy for treatment in patients with type 2 diabetes in the United States

Efficacy and safety of imeglimin in Japanese patients with type 2 diabetes: A 24-week, randomized, double-blind, placebo-controlled, dose-ranging phase 2b trial

A 52-week randomized controlled trial of ipragliflozin or sitagliptin in type 2 diabetes combined with metformin: The N-ISM study

Comparative efficacy and safety of glucose-lowering drugs as adjunctive therapy for adults with type 1 diabetes: A systematic review and network meta-analysis

BRIEF REPORTS

Metformin dose increase versus added linagliptin in non-alcoholic fatty liver disease and type 2 diabetes: An analysis of the J-LINK study

How many people with type 2 diabetes fulfil the eligibility criteria for randomized, controlled trials of insulin glargine 300 U/mL in a real-world setting?

Results from the Effects of MEtformin on cardiovasculaR function in AdoLescents with type 1 Diabetes (EMERALD) study: A brief report of kidney and inflammatory outcomes

Weight-loss response to naltrexone/bupropion is modulated by the Taq1A genetic variant near DRD2 (rs1800497): A pilot study

Efficacy and safety of adding sotagliflozin, a dual sodium-glucose co-transporter (SGLT)1 and SGLT2 inhibitor, to optimized insulin therapy in adults with type 1 diabetes and baseline body mass index ≥ 27 kg/m2

Extended-release naltrexone/bupropion and liver health: Pooled, post hoc analysis from four randomized controlled trials

LETTER TO THE EDITOR

Mean basal insulin dose is 0.2 U/kg/d at near normal glycaemia for type 1 or 2 diabetes on continuous subcutaneous insulin infusion or once-nightly basal insulin

Proportion of newly diagnosed diabetes in COVID-19 patients: A systematic review and meta-analysis

Sign up for email alerts

Tools

October 2023 Trending Article

More From This Journal

Dose-dependent accumulation of glucose in the intestinal wall and lumen induced by metformin as revealed by ¹⁸F-labelled fluorodeoxyglucose positron emission tomography-MRI

Prediction of heart failure outcomes in patients with type 2 diabetes mellitus: Validation of the Thrombolysis in Myocardial Infarction Risk Score for Heart Failure in Diabetes (TRS-HF_DM) in patients in the ACCORD trial

Efficacy and safety of adding sotagliflozin, a dual sodium-glucose co-transporter (SGLT)1 and SGLT2 inhibitor, to optimized insulin therapy in adults with type 1 diabetes and baseline body mass index ≥ 27 kg/m²